Program for Resistance, Immunology, Surveillance & Modeling of Malaria in Uganda (PRISM) Renewal
Project Number3U19AI089674-12S1
Contact PI/Project LeaderDORSEY, MATTHEW G
Awardee OrganizationUNIVERSITY OF CALIFORNIA, SAN FRANCISCO
Description
Abstract Text
Summary/Abstract
Malaria remains one of the most important global health challenges, with an estimated 215 million cases and
438 thousand deaths each year. Malaria disproportionately affects sub-Saharan Africa, where 88% of cases
and 90% of deaths occur. There has recently been a dramatic increase in the scale up of control interventions
and reduction in the burden of malaria across Africa. However, progress has not been uniform, and in fact has
been slowest in countries with the highest burden, such as Uganda. Our program called “PRISM” has been
based in Uganda, representing the East African region for the International Centers of Excellence for Malaria
Research network. Uganda is emblematic of the challenges faced by high burden countries, where routine
surveillance systems are inadequate to assess trends in the burden of malaria or to monitor the impact of
control interventions. Through PRISM we have implemented a comprehensive malaria surveillance program
including enhanced health facility-based surveillance and detailed longitudinal studies in three regions with
differing transmission intensities. Complementary laboratory-based studies include surveillance for markers of
antimalarial drug and insecticide resistance and serologic measures of malaria exposure. These studies have
greatly improved our understanding of the epidemiology of malaria in Uganda and of the impact of control
interventions. In this renewal application we propose to continue key components of our malaria surveillance
work, but to expand our scope to address more fundamental questions about interactions between the
parasite, mosquito vector, and human host. More intensive longitudinal evaluations will be conducted and
cutting edge molecular studies will be added to better measure exposure to infective bites; more sensitively
identify bloodstream infections; characterize parasite, vector, and human genetic factors that impact on
malaria; and assess impacts of these factors on infectivity and transmission. The program will consist of three
research projects linked together in an integrated manner to maximize scientific discovery. Research project 1
(Resistance project) will use samples collected over time at multiple sites to characterize the evolution of
phenotypic and genotypic markers of drug and insecticide resistance and assess the impacts of these markers
on malaria transmission. Research project 2 (Epidemiology project) will use longitudinal samples from cohorts
to characterize factors that determine whether sporozoite inoculation results in the establishment of blood
stage infection and characterize factors affecting the duration, density, and clinical consequences of blood
stage infections. Research project 3 (Transmission project) will use cohort samples to determine factors
associated with gametocyte production and development, evaluate infectivity of the human host to mosquito
vectors, and characterize the human infectious reservoir. These highly interrelated projects will be conducted
in settings with varied malaria epidemiology and differing population level control intervention to provide critical
information needed to optimize strategies for the control and ultimate elimination of malaria in Uganda.
Public Health Relevance Statement
Project Narrative
Recent increases in funding and resources have provided Africa with the opportunity to greatly reduce the
burden of malaria. However, gaps in knowledge remain as to the optimal approaches to malaria control in
different epidemiological setting. The central theme of this proposal will be to improve our understanding of
factors that influence infection, disease, and transmission in Uganda in the context of different transmission
intensities and population level control interventions.
NIH Spending Category
No NIH Spending Category available.
Project Terms
AddressAffectAfricaAfrica South of the SaharaAfricanAnti-malarial drug resistanceArtemisininsBiteBloodCarbamatesCessation of lifeClinicalClinical DataCombined Modality TherapyCountryDevelopmentDiseaseDrug resistanceEpidemiologyEvaluationEvolutionExposure toFundingGenotypeHealth care facilityHumanHuman GeneticsImmunologyIncidenceIndividualInfectionInsecticide ResistanceInsecticidesInterventionKnowledgeLaboratoriesLinkLongitudinal StudiesMalariaMeasuresMolecularMonitorMorbidity - disease rateOutcomeParasitesPharmaceutical PreparationsPhenotypePlasmodium falciparumPopulationProductionResearchResearch Project GrantsResidual stateResistanceResource SharingResourcesRiskSamplingSepsisSerologySiteSpecimenSporozoitesSurveillance ModelingSurveillance ProgramSystemTimeUgandaWorkbasecohortdensitydisease transmissioneffective therapyglobal healthimprovedinternational centermalaria transmissionnovelprogramspyrethroidscale upsurveillance studytransmission processtrendvectorvector mosquito
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
094878337
UEI
KMH5K9V7S518
Project Start Date
01-July-2010
Project End Date
31-March-2024
Budget Start Date
23-April-2021
Budget End Date
31-March-2022
Project Funding Information for 2021
Total Funding
$783,771
Direct Costs
$783,771
Indirect Costs
Year
Funding IC
FY Total Cost by IC
2021
National Institute of Allergy and Infectious Diseases
$783,771
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 3U19AI089674-12S1
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 3U19AI089674-12S1
Patents
No Patents information available for 3U19AI089674-12S1
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 3U19AI089674-12S1
Clinical Studies
No Clinical Studies information available for 3U19AI089674-12S1
News and More
Related News Releases
No news release information available for 3U19AI089674-12S1
History
No Historical information available for 3U19AI089674-12S1
Similar Projects
No Similar Projects information available for 3U19AI089674-12S1